Guardant Health (GH) stock

Cancer tests , market cap $21B

Cancer tests for clinical and research use

Worth $21B

$155.35

-2.17%

As of Tuesday's close · Live for Pro members at the open

Why is GH down?

Down 16% from Oct 29 to Nov 10.

Guardant Health fell 16% from Oct 29 to Nov 10. 8 points of it came on Nov 5.

Sources: Price history, Nov 10, 2026

Tell me next time GH moves

Free account, no card. An optional alert when GH moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why GH is down 16% since Oct 29, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Quality Score

Above Average

In its industry

#6of 18

Diagnostics

Checks firing

2of 14

Transition

From 52-week high

-18.7%

under its best in a year

GH's Quality Score rose 1 point on Tue, Nov 10, to 12. The Sep 15 sale of $1.4M by Darya Chudova (Chief Technology Officer) counts for less as it ages.

See GH's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on GH

Key facts on GH
The company	Sales up 42% on the year
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind GH's 12, free with an account →8 more reasons behind GH's 12, for Pro members.

GH in the news

Fri Nov 6Guardant Health reported $361.0 million of quarterly revenue and a loss of $0.93 a share SEC, 4:08 PM ET GH closed −1.7% that day.

What's next

Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

GH catalysts

Coming up

After its last 4 reports it closed +1.3% on average, higher 2 of 4 times.

22 past catalysts since 2019, with sizes and sources, for Pro members.

Why GH scores 12

Above Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+3Growth sales up 42% on the year, gross margin up 1.4 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
+3News guidance raised, earnings beat

Chart checks adds
Long-term trend adds
Run-up adds
Size adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Persistence adds
Government filings adds

No effect today: Dilution and Insider trades.

What every line is worth, and the reason behind it, on GH and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How GH ranks in Diagnostics

GH is #6 of 18 by Quality Score.

How GH ranks in Diagnostics
Rank	Stock	Checks	Quality Score
1	CDNACareDx	4/14	16
2	BLLNBillionToOne	5/14	16
3	LHLabcorp	7/14	16
	DGXQuest Diagnostics		Open for its score
	FRNMFreenome		Open for its score
	GRALGRAIL		Open for its score
6	GHGuardant Health	2/14	12

Share count against a year before: GH +7.7%, LH -2.4%, NTRA +5%.

When does GH report earnings, and what happens after?

Expected to report Thu Feb 18, after the close (in 100 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GH reported on Nov 5, 2026

The quarter

Sales of $361.0M, 36% more than a year ago; a loss of $0.93 a share, from $0.74.

“Reported total revenue of $361.0 million, an increase of 36%, driven by:”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Oncologyup 25%	$231M64%	$219M65%	$184M70%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

5 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total revenue	$1.36B to $1.37Braised

Figures as filed (SEC filing, Nov 5)

8 more outlook lines, for Pro members.

In the company's words

“Screening revenue grew 180% to $67.6 million for the third quarter of 2026, from $24.1 million for the corresponding prior year period, driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value: $21B; today
Sales: $1.3B; up 41.7% on the year
Free cash flow: -$232M; last 12 months

Sales grew 28% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.2% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GH: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+3.7%+6.3%-1.7%

May 7Jul 30Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	-7.6%	-1.7%	not yet
Jul 30, 2026After close	After close	+6.7%	+6.3%	+3.4%
May 7, 2026After close	After close	+4.7%	+3.7%	+6.9%

GH closed higher after 2 of its last 4 reports.

All 4 reports, and GH's Quality Score going into each

GH sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $982M. It lost money in each of the seven years.

GH has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on GH, and all 14 on every stock.Get in free →

GH RSI today: 41.3, below its 50-day, above its 200-day

Not scored

RSI 41.3, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on GH

What it does and how it makes money5 findingsAn operating loss of $437M in fiscal 2025, on $982M of sales.Annual report, filed Feb 19, 2026"Issued U.S. patents and their international counterparts currently in our patent portfolio that relate to various aspects of our technology and products are expected to expire between 2028 and 2045." (10-K for fiscal 2025)SEC filing · Feb 19, 2026
Where it stands4 findingsFor Pro members4 findings on where GH stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"On June 16, 2026, the District Court ruled on the motions, denying the Company’s motion to overturn the jury’s verdict, seek a new trial, and/or amend the judgment." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026One customer made up 28% of its revenue in fiscal 2025, down from 29% in fiscal 2024.SEC filing · Feb 19, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades GH, for Pro members
Against its closest peers3 peersShare count against a year before: GH +7.7%, LH -2.4%, NTRA +5%.

13 more findings on GH, each with its source, for Pro members.

GH share count over time

Shares: 7.7% more than a year ago (to Sep 30).

Shares of GH outstanding, as filed
Shares outstanding	As of
135.3M	Oct 30, 2026
134.2M	Jul 24, 2026
132.6M	May 1, 2026
131.2M	Feb 13, 2026

Offerings, shelves, and splits of GH, from its filings
From its filings	Filed
Sold convertible notes	Nov 6, 2025

GH insider trades

One insider bought $78K across 1 filing, and 10 insiders sold $49.8M across 40 filings, in the last 6 months. The newest:

SellDarya Chudova$1.4MChief Technology Officerat $178.00 on Sep 15, filed Sep 17

SellDarya ChudovaChief Technology Officer$1.4Mat $178.00 on Sep 15, filed Sep 17

All 41 insider filings on GH from the last six months, for Pro members.

All GH insider trades

GH trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

BuyJonathan Jackson$15K to $50KHousetraded Sep 28, disclosed Oct 19(21 days later)

BuyJonathan JacksonHouse$15K to $50Ktraded Sep 28, disclosed Oct 19(21 days later)

See what Congress is buying across the market

GH's officers and directors

Officers and directors with a Form 4 in the last 12 months.

AmirAli TalasazCo-Chief Executive Officer · 10 trades
Helmy EltoukhyCo-Chief Executive Officer · 2 trades
Michael Brian BellChief Financial Officer · 13 trades
Chris FreemanChief Commercial Officer · 16 trades
Terilyn J. MonroeChief People Officer · 9 trades
Kumud KaliaChief Information Officer · 7 trades
Darya ChudovaChief Technology Officer · 4 trades
John G. SaiaChief Legal Officer · 2 trades

10 more officers and directors file at GH.

See insider trades by person

Which ETFs hold GH?

In ETFs: GH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Guardant Health

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

2,506 employeesPalo Alto, CAguardanthealth.com

What Guardant Health says it competes with

“The promise of liquid biopsy testing is also leading to more companies attempting to enter the space and compete with us.”

From its annual report, SEC filing · Feb 19, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on GH and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move GH's score: 6 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 19Jonathan Jackson bought GH$15K to $50K, disclosed Oct 19

Alerts are optional.

See GH's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: GH's Quality Score is 12 (Above Average), #6 of 18 in Diagnostics. Insiders bought $78K and sold $49.8M in the last 6 months (Form 4).

What does GH's Quality Score say?

GH scores 12 today, which Breakaway calls Above Average. It is #6 of 18 in Services-⁠Medical Laboratories by Quality Score, with 2 of 14 chart checks firing. Down 16% from Oct 29 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GH's Quality Score?

GH scores 12 today, which Breakaway calls Above Average (11 to 14). That is #6 of 18 in Services-⁠Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GH's 12.

Are insiders buying GH?

One insider bought $78K across 1 filing, and 10 insiders sold $49.8M across 40 filings, in the last 6 months. The newest is Darya Chudova, Chief Technology Officer, who sold $1.4M on Sep 15. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.